Fagron NV
XBRU:FAGR

Watchlist Manager
Fagron NV Logo
Fagron NV
XBRU:FAGR
Watchlist
Price: 23.6 EUR Market Closed
Market Cap: €1.7B

Fagron NV
Capital Expenditures

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Fagron NV
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Fagron NV
XBRU:FAGR
Capital Expenditures
-€30.6m
CAGR 3-Years
-18%
CAGR 5-Years
-11%
CAGR 10-Years
N/A
No Stocks Found

Fagron NV
Glance View

Fagron NV is a Belgian multinational company that has woven specialized pharmaceutical compounding into the fabric of modern healthcare. Founded in 1990, the company's mission has always been to advance personalized medicine by focusing on the compounding sector, which involves tailoring and mixing pharmaceutical ingredients to produce unique medications tailored to the specific needs of patients. By transforming individual healthcare demands into bespoke pharmaceutical solutions, Fagron serves the global medical community by manufacturing and distributing both active and inactive pharmaceutical ingredients, as well as offering various base products. This strategic positioning not only supports healthcare professionals and pharmacies in delivering specialized patient care but also fortifies the company's commitment to improving global health outcomes. The key to Fagron's business model lies in its adept integration of innovation alongside therapeutic and technological solutions, ensuring they maintain a strong presence within the compounding market. The company particularly thrives on its ability to address niches in the pharmaceutical industry, ones often overlooked by large pharma entities due to scale inefficiencies. Through its three principal segments—Pharmaceutical Compounding, Raw Materials, and Innovative Concepts—Fagron generates revenue by supplying pharmacies and medical institutions worldwide, from small community pharmacies to large hospital networks. Its broad portfolio of over 30,000 products caters to a spectrum of needs, fostering both patient-specific and bulk pharmaceutical solutions. By combining quality, safety, and regulatory compliance with a keen market understanding, Fagron NV continues to sustain its role as a crucial player in the personalized medicine arena.

FAGR Intrinsic Value
27.88 EUR
Undervaluation 15%
Intrinsic Value
Price €23.6

See Also

What is Fagron NV's Capital Expenditures?
Capital Expenditures
-30.6m EUR

Based on the financial report for Dec 31, 2025, Fagron NV's Capital Expenditures amounts to -30.6m EUR.

What is Fagron NV's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-11%

Over the last year, the Capital Expenditures growth was 25%. The average annual Capital Expenditures growth rates for Fagron NV have been -18% over the past three years , -11% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett